These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36656233)

  • 1. Clinician's dilemma: Naproxen-induced liver injury.
    Sharma S; Sharma A; Surya M; Guleria S; Bansal N
    Indian J Pathol Microbiol; 2023; 66(1):168-170. PubMed ID: 36656233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
    Eccleston C; Cooper TE; Fisher E; Anderson B; Wilkinson NM
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012537. PubMed ID: 28770976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe reversible renal failure due to naproxen-associated acute interstitial nephritis.
    Becker-Cohen R; Frishberg Y
    Eur J Pediatr; 2001 May; 160(5):293-5. PubMed ID: 11388597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis.
    De Silva B; Banney L; Uttley W; Luqmani R; Schofield O
    Pediatr Dermatol; 2000; 17(6):480-3. PubMed ID: 11123786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.
    Lovell DJ; Dare JA; Francis-Sedlak M; Ball J; LaMoreaux BD; Von Scheven E; Reinhardt A; Jerath R; Alpan O; Gupta R; Goldsmith D; Zeft A; Naddaf H; Gottlieb B; Jung L; Holt RJ
    Pediatr Rheumatol Online J; 2018 Jun; 16(1):41. PubMed ID: 29941047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate/naproxen-associated severe hepatitis in a child with juvenile idiopathic arthritis.
    Ting TV; Hashkes PJ
    Clin Exp Rheumatol; 2007; 25(6):928-9. PubMed ID: 18173932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case 1: Naproxen-induced pseudoporphyria.
    O'Donoghue NB; Higgins EM
    Clin Exp Dermatol; 2002 Jun; 27(4):339-40. PubMed ID: 12139696
    [No Abstract]   [Full Text] [Related]  

  • 8. Naproxen-induced liver injury.
    Ali S; Pimentel JD; Ma C
    Hepatobiliary Pancreat Dis Int; 2011 Oct; 10(5):552-6. PubMed ID: 21947732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naproxen-induced pseudoporphyria: appearance of new skin lesions after discontinuation of treatment.
    Girschick HJ; Hamm H; Ganser G; Huppertz HI
    Scand J Rheumatol; 1995; 24(2):108-11. PubMed ID: 7747141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results.
    Ruperto N; Nikishina I; Pachanov ED; Shachbazian Y; Prieur AM; Mouy R; Joos R; Zulian F; Schwarz R; Artamonova V; Emminger W; Bandeira M; Buoncompagni A; Foeldvari I; Falcini F; Baildam E; Kone-Paut I; Alessio M; Gerloni V; Lenhardt A; Martini A; Hanft G; Sigmund R; Simianer S;
    Arthritis Rheum; 2005 Feb; 52(2):563-72. PubMed ID: 15692986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudoporphyria induced by propionic acid derivatives.
    Al-Khenaizan S; Schechter JF; Sasseville D
    J Cutan Med Surg; 1999 Jan; 3(3):162-6. PubMed ID: 10082597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis.
    Leak AM; Richter MR; Clemens LE; Hall MA; Ansell BM
    Clin Exp Rheumatol; 1988; 6(2):157-60. PubMed ID: 3052965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naproxen nephrotoxicity in a 2-year-old child.
    Ray PE; Rigolizzo D; Wara DR; Piel CF
    Am J Dis Child; 1988 May; 142(5):524-5. PubMed ID: 3358393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis.
    Lang BA; Finlayson LA
    J Pediatr; 1994 Apr; 124(4):639-42. PubMed ID: 8151484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naproxen-induced fixed drug eruption: a case report.
    Akyazi H; Baltaci D; Mungan S; Kara IH
    Hum Exp Toxicol; 2011 Nov; 30(11):1872-4. PubMed ID: 21357631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paucity of renal complications associated with nonsteroidal antiinflammatory drugs in children with chronic arthritis.
    Szer IS; Goldenstein-Schainberg C; Kurtin PS
    J Pediatr; 1991 Nov; 119(5):815-7. PubMed ID: 1941392
    [No Abstract]   [Full Text] [Related]  

  • 17. [Naproxen-induced pseudoporphyria].
    Maerker JM; Harm A; Foeldvari I; Höger PH
    Hautarzt; 2001 Nov; 52(11):1026-9. PubMed ID: 11757457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.
    Solomon DH; Husni ME; Libby PA; Yeomans ND; Lincoff AM; Lϋscher TF; Menon V; Brennan DM; Wisniewski LM; Nissen SE; Borer JS
    Am J Med; 2017 Dec; 130(12):1415-1422.e4. PubMed ID: 28756267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis.
    Krug H; Broadwell LK; Berry M; DeLapp R; Palmer RH; Mahowald M
    Clin Ther; 2000 Jan; 22(1):40-52. PubMed ID: 10688389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term followup of naproxen-induced pseudoporphyria in juvenile rheumatoid arthritis.
    Mehta S; Lang B
    Arthritis Rheum; 1999 Oct; 42(10):2252-4. PubMed ID: 10524703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.